Literature DB >> 10499722

Combination allopurinol and antimony treatment versus antimony alone and allopurinol alone in the treatment of canine leishmaniasis (96 cases).

P Denerolle1, G Bourdoiseau.   

Abstract

The aim of the present study was to evaluate the long-term clinical outcome for dogs with leishmaniasis that were treated with 3 different protocols: combined treatment with antimony and allopurinol, antimony alone, or allopurinol alone. Ninety-six dogs included in this study were determined to have leishmaniasis on the basis of (1) clinical features, (2) identification of the parasite in smears of lymph node, bone marrow aspirates, or skin biopsies, and (3) specific immunofluorescent assay. Three groups of dogs were defined: 45 dogs (group 1) were treated with antimony (100 mg/kg s.c. q24h) given concurrently for 1 month with allopurinol (15 mg/kg p.o. q12h), and then allopurinol alone for 8 months at the same dosage; 40 dogs (group 2) were treated with antimony alone according to the manufacturer's instructions (200 mg/kg s.c. q24h at 2-day intervals for 3-6 months); and 11 dogs (group 3) were treated with allopurinol alone (15 mg/kg p.o. q12h for 1-20 months). Information concerning signalment, history, physical examination findings, serologic testing and number of dogs becoming seronegative, outcome for each treated dog (clinical cure versus failure), and long-term survival were recorded. The numbers of the clinical cures versus failures were significantly different among the 3 groups (chi2 = 17.77, P < .001), between groups 1 and 2 (chi2 = 8.02, P < .01), between groups 2 and 3 (chi2 = 11.00, P < .01), and between groups 1 and 3 (chi2 = 16.52, P < .001). No significant difference between groups 1 and 2 was noted in the type of failure (relapse or death), serologic test results, and number of survival years (chi2 = 2.79, P > .05). The results of the present study indicate that antimony in combination with allopurinol produces better results than antimony alone or allopurinol alone for the treatment of the canine leishmaniasis. With combination treatment, duration of treatment with antimony is shorter and long-term administration of allopurinol is well tolerated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499722     DOI: 10.1892/0891-6640(1999)013<0413:caaatv>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  19 in total

1.  Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro.

Authors:  S W Kamau; F Grimm; A B Hehl
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

2.  Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs.

Authors:  Felicitat Todolí; Inmaculada Galindo; Silvia Gómez-Sebastián; Mariano Pérez-Filgueira; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

3.  Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.

Authors:  Anna Maria Farca; B Miniscalco; P Badino; R Odore; P Monticelli; A Trisciuoglio; E Ferroglio
Journal:  Parasitol Res       Date:  2012-01-05       Impact factor: 2.289

4.  Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

Authors:  Joelma Trigo; Melissa Abbehusen; Eduardo M Netto; Maria Nakatani; Geraldo Pedral-Sampaio; Robson Silva de Jesus; Yasuyuki Goto; Jeffrey Guderian; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

5.  Efficacy of combined therapy with liposome-encapsulated meglumine antimoniate and allopurinol in treatment of canine visceral leishmaniasis.

Authors:  Sydnei M da Silva; Izabela F G Amorim; Raul R Ribeiro; Erly G Azevedo; Cynthia Demicheli; Maria N Melo; Wagner L Tafuri; Nelder F Gontijo; Marilene S M Michalick; Frédéric Frézard
Journal:  Antimicrob Agents Chemother       Date:  2012-03-12       Impact factor: 5.191

6.  Purine nucleobase transport in amastigotes of Leishmania mexicana: involvement in allopurinol uptake.

Authors:  Mohammed I Al-Salabi; Harry P de Koning
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

7.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

8.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

9.  Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis.

Authors:  Virginie Woerly; Laurence Maynard; Annaële Sanquer; Hyone-Myong Eun
Journal:  Parasitol Res       Date:  2009-03-26       Impact factor: 2.289

10.  Successful treatment of canine cutaneous leishmaniasis using radio-frequency induced heat (RFH) therapy.

Authors:  Anil A Ahuja; Ram A Bumb; Rajesh D Mehta; Neha Prasad; Ram K Tanwar; Abhay R Satoskar
Journal:  Am J Trop Med Hyg       Date:  2012-08       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.